

GLAXOSMITHKLINE PLC
Form 6-K
October 18, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 17 October 2016

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Dr M M Slaoui
- b) Position/status Chairman, Global Vaccines
- c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument American Depository Shares ('ADSs')
ISIN: US37733W1053
Increase in notional interest in ADSs following the re-investment of dividends
- b) Nature of the transaction paid to shareholders on 13 October 2016 on ADSs held in the Company's 2009 Performance Share Plan.
- c) Price(s) and volume(s)

Price(s)	Volume(s)
\$42.39	1414.687
\$42.39	1569.750
\$42.39	1797.585

Aggregated information

- d) Aggregated volume 4,782.022
- Price \$42.39

- e) Date of the transaction 2016-10-13

- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr N Hirons
- b) Position/status SVP, Global Ethics & Compliance
- c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793
 Details of the transaction(s): section to be repeated for (i) each type of
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transaction(s) has been conducted

a) Description of the financial instrument American Depository Shares ('ADSs')
 ISIN: US37733W1053
 Increase in notional interest
 in ADSs following the
 re-investment of dividends
 b) Nature of the transaction paid to shareholders on 13
 October 2016 on ADSs held
 in the Company's 2009
 Performance Share Plan.

c) Price(s) and volume(s) Price(s) Volume(s)
 \$42.39 85.247

Aggregated information

d) Aggregated volume n/a (single transaction)
 Price

e) Date of the transaction 2016-10-13

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr B McNamara
 b) Position/status CEO, GSK Consumer
 Healthcare

c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction
 platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transaction(s) has been conducted

a) Description of the financial instrument American Depository Shares ('ADSs')
 ISIN: US37733W1053
 Increase in notional interest
 in ADSs following the
 re-investment of dividends
 b) Nature of the transaction paid to shareholders on 13
 October 2016 on ADSs held
 in the Company's 2009
 Performance Share Plan.

c) Price(s) and volume(s) Price(s) Volume(s)
 \$42.39 42.422

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

\$42.39	71.440
\$42.39	211.994
\$42.39	357.084
\$42.39	551.108

Aggregated information

d) Aggregated volume	1234.048
Price	\$42.39
e) Date of the transaction	2016-10-13
f) Place of the transaction	n/a
1. Details of PDMR/person closely associated with them ('PCA')	
a) Name	Mr D E Troy
b) Position/status	SVP & General Counsel
c) Initial notification/ amendment	Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	
a) Description of the financial instrument	American Depositary Shares (‘ADSs’) ISIN: US37733W1053 Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 October 2016 on ADSs held in the Company's 2009 Performance Share Plan.
b) Nature of the transaction	
c) Price(s) and volume(s)	Price(s) Volume(s) \$42.39 876.858 \$42.39 972.968 \$42.39 1128.822

Aggregated information

d) Aggregated volume	2978.648
Price	\$42.39
e) Date of the transaction	2016-10-13
f) Place of the transaction	n/a
1. Details of PDMR/person closely associated with them ('PCA')	
a) Name	Dr K Slaoui
b) Position/status	PCA of Dr M M Slaoui (Chairman, Global Vaccines)
c) Initial notification/ amendment	Initial notification

amendment

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument American Depository Shares ('ADSs')
ISIN: US37733W1053
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 October 2016 on ADSs held in the Company's 2009 Performance Share Plan.
 - b) Nature of the transaction
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
\$42.39	22.991
\$42.39	24.324
\$42.39	25.675
 - d) Aggregated information

Aggregated volume	72.99
Price	\$42.39
 - e) Date of the transaction 2016-10-13
 - f) Place of the transaction n/a

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)
Date: October 17, 2016

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc